Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and FLOT Chemotherapy in Gastric or GEJ Adenocarcinoma
NCT07631000Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Event-free survival at 18 months. Started May 2026; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07631000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631000.